Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Egypt's cafés and shops forced to close early due to Iran war - 2German hauliers warn soaring energy prices may soon impact consumers
- 3Vote in favor of Your #1 BWM Vehicles
- 4Chris Noth responds to backlash after seemingly shading 'Sex and the City' costar Sarah Jessica Parker: 'It is not news'
- 5UN estimates over 2,000 Sudanese pregnant women have fled el-Fasher to escape conflict
- Should you get an RSV vaccine this fall? What to know and where to get a shot
- Which Instax Camera Would it be a good idea for you to Purchase?
- Hundreds of kilos of protected plant seized by Israel Nature and Parks Authority in Golan
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- Clocks to go forward one hour in Europe as summer time starts
- April's full moon decides the date of Easter — here's how it works
- Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground
- Remains of banker missing since 1999 found on California beach by family looking for seashells
